• Oct 5, 2026

  $139.54-3.30%

  Merck closed down 3.30%, a larger fall than the comparable pharmaceutical companies, which moved -0.48% on average, with 4 of 6 falling [3]. The move was therefore largely not shared by the cohort. The headlines held for the day concerned personalized mRNA cancer vaccines in general and another company's pneumonia vaccine data, and neither reports a development at Merck [1][2].

  • 1Seeking Alpha
  • 2Seeking Alpha
  • 3Peer group

• Oct 2, 2026

  $144.30+0.34%

• Oct 1, 2026

  $143.81-1.03%

  Comparable pharmaceutical preparations companies fell 1.85% on average, with all 6 of 6 falling [1]. The company's own decline of 1.03% came alongside that sector-wide weakness [1].

  • 1Peer group

• Sep 30, 2026

  $145.31-2.66%

  Merck fell 2.66%, while comparable pharmaceutical companies fell 1.26% on average, with all 6 of 6 lower [2]. Seeking Alpha reported that Merck posted a mid-stage trial success for tulisokibart in hidradenitis suppurativa [1]. The decline was larger than the sector's, and the trial news did not coincide with a gain.

  • 1Seeking Alpha
  • 2Peer group

• Sep 29, 2026

  $149.28+0.40%

• Sep 28, 2026

  $148.69-0.06%

  Seeking Alpha reported that Merck signed a license deal worth up to $2.13B with SciBrunch for its SPR2015 KRAS G12D inhibitor [1]. The summary said the deal included a $400M charge in the third quarter of 2026 [1]. Shares closed down 0.06%, a marginal move.

  • 1Seeking Alpha

• Sep 25, 2026

  $148.78+0.54%

  Merck withdrew its Biologics License Application for the antibody-drug conjugate I-DXd in small cell lung cancer, as reported by Seeking Alpha [1].

  • 1Seeking Alpha

Closing prices for MRK. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.